References
- Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, et al. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups. Biol Blood Marrow Transplant. 2015;21(11):1883–1887. doi:https://doi.org/10.1016/j.bbmt.2015.09.005.
- Cervantes F, Vannucchi AM, Kiladjian -J-J, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–4053. doi:https://doi.org/10.1182/blood-2013-02-485888.
- Martinez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Díaz-Beyá M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol. 2010;89(12):1233–1237. doi:https://doi.org/10.1007/s00277-010-1019-9.
- Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM. Beyond ruxolitinib: fedratinib and other emergent treatment options for myelofibrosis. Cancer Manag Res. 2019;11:10777–10790. doi:https://doi.org/10.2147/CMAR.S212559.
- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061. doi:https://doi.org/10.1016/S0140-6736(05)71142-9.
- Harrison CN, Schaap N, Vannucchi AM, Kiladjian -J-J, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317–e324. doi:https://doi.org/10.1016/S2352-3026(17)30088-1.
- Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643–651. doi:https://doi.org/10.1001/jamaoncol.2015.1590.
- Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369(7):681–683. doi:https://doi.org/10.1056/NEJMc1302895.
- Yan Z, Gibson SA, Buckley JA, Qin H, Benveniste EN. Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin Immunol. 2018;189:4–13. doi:https://doi.org/10.1016/j.clim.2016.09.014.
- Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21–27. doi:https://doi.org/10.4049/jimmunol.1401867.
- Irey EA, Lassiter CM, Brady NJ, et al. JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors. Proc Natl Acad Sci U S A. 2019;116(25):12442–12451.
- Pirbhai A, Rajak SN, Goold LA, Cunneen TS, Wilcsek G, Martin P, et al. Bisphosphonate-induced orbital inflammation: a case series and review. Orbit. 2015;34(6):331–335. doi:https://doi.org/10.3109/01676830.2015.1078380.